Pseudomonas Aeruginosa Infections Treatment Market : Global Industry Competitive Landscape & Technological Breakthroughs
Pseudomonas aeruginosa, a rod-shaped bacterium, is usually found in moist or wet areas such as water and soil. Pseudomonas aeruginosa infection is the most common type of Pseudomonas infections and is caused by strain of bacteria abundantly found in the environment.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1362758
This bacterial strain usually do not cause harm in healthy people but are ‘opportunistic’ pathogens to cause infection in patients with compromised immune function. Therefore, the main threat is posed to most vulnerable subjects such as hospitalized patients, particularly those in intensive care units, and cancer patients, people with severe burns, and babies in the neonatal units. Pseudomonas aeruginosa is listed as one of the six most dangerous drug-resistant microbes and more than 15% of P. aeruginosa isolates were found resistant to at least three classes of antibiotics which signifies the huge treatment gap present today.
Pseudomonas Aeruginosa Infections can involve several parts of body and the severity and type of illness depends on its entry route and site into the body. Various sites where this infection can cause harm are respiratory tract, blood stream, gastrointestinal tract, urinary tract, cardiovascular system, nervous system, ear, eye, bones and joints, and skin. Pseudomonal infections often become complicated to mange and can be life-threatening. Pseudomonas infections are usually treated with antibiotics. However, antibiotic resistance for these infections is increasing which makes more difficult to treat. The economic burden of healthcare associated infection (HAIs) is very high which have increased the demand for solutions that can be helpful in reducing these infections and the costs associated with them.
Global Pseudomonas Aeruginosa Infections Treatment Market: Trends and Opportunities
Multi-drug resistant (MDR) Pseudomonas poses life threatening danger to patients in critical care. In the U.S. more than 51,000 P. aeruginosa infections occur annually which are associated with healthcare settings such as nursing homes and hospitals. Out of these more than 13% are multidrug-resistant (MDR) phenotype. These multidrug resistance Pseudomonas infections have been highlighted with serious level of threat in a report ‘Antibiotic resistance threats in the United States, 2013’ presented by the Centers for Disease Control and Prevention (CDC). This eventually presents a market opportunity for the companies which can provide solutions in terms of diagnostics, treatment and prevention of Pseudomonas aeruginosa infections. The market for Pseudomonas aeruginosa infections treatment is driven by rate of mortality and lack of drugs which can combat MDR phenotypes of P. aeruginosa. Several pharmaceutical companies are striving to bring innovative drugs into market which can treat Pseudomonas infections.
Make an Enquiry about TOC @ https://www.researchmoz.us/enquiry.php?type=E&repid=1362758
The large companies such as Roche has been trying to capitalize the unmet market needs through collaboration and licensing agreements. For instance, Roche entered into an exclusive worldwide agreement with Polyphor Ltd., to develop and commercialize latter company’s investigational antibiotic, POL7080. The companies in the market have historically focused in the United States and Europe. However, with the increasing competition in these geographies, the larger players are encouraged to engage in untapped markets in Asia and Latin America.
Global Pseudomonas Aeruginosa Infections Treatment Market: Key Players
Some of the companies in the global Pseudomonas aeruginosa infections treatment market include Achaogen, Inc., AmpliPhi Biosciences Corporation, Aridis Pharmaceuticals LLC, Cantab Biopharmaceuticals Ltd., FOB Synthesis, Inc., Forest Laboratories, Inc., GlycoVaxyn AG, Insmed, Inc., KaloBios Pharmaceuticals, Inc., Lytix Biopharma AS, Melinta Therapeutics, Inc., Microbiotix, Inc., Novabiotics Ltd., Omnia Molecular Ltd., PARI Pharma GmbH, Pfizer, Inc., Pherecydes Pharma SA., Phico Therapeutics Ltd., Polyphor Ltd., Procarta Biosystems Ltd., Sequoia Sciences, Inc., Soligenix, Inc., Tetraphase Pharmaceuticals, Inc., Therametrics Holding AG, and Trana Discovery, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/pseudomonas-aeruginosa-infections-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/